Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma

被引:11
|
作者
Adashek, Jacob J. [1 ]
Salgia, Meghan [1 ]
Dizman, Nazli [1 ]
Kessler, Jonathan [1 ]
Pal, Sumanta K. [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, 1500 East Duarte Rd, Duarte, CA 91010 USA
来源
CASE REPORTS IN ONCOLOGY | 2018年 / 11卷 / 02期
关键词
Radioembolization; Metastatic renal cell carcinoma; Immune checkpoint inhibition; Internal radiotherapy; Immunotherapy;
D O I
10.1159/000489995
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This case represents the challenge and creativity necessary when treating patients with metastatic renal cell carcinoma who have been exposed to multiple lines of therapy. At present, treatment with immune checkpoint inhibition has stabilized and improved the metastatic disease of this patient with the exception of hepatic lesions. This isolated progression within the liver led the employment of radioembolization, which successfully treated those metastases. This is the first documented case of metastatic renal cell carcinoma controlled with concurrent use of immune checkpoint inhibition and radioembolization for both extrahepatic and hepatic metastases, respectively. This case can be construed as a potential example of the abscopal effect and may provide the basis for understanding this type of response in select patients. (C) 2018 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:276 / 280
页数:5
相关论文
共 50 条
  • [1] Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
    Saliby, R. M.
    Jammihal, T.
    Labaki, C.
    Soulati, H.
    Gallegos, J.
    Peris, A.
    McCurry, D.
    Yu, C.
    Shah, V.
    Poduval, D.
    El Zarif, T.
    El Ahmar, N.
    Laimon, Y. N.
    Heng, D. Y. C.
    Signoretti, S.
    Van Allen, E. M.
    Choueiri, T. K.
    Shukla, S.
    Braun, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1017 - S1017
  • [2] Immune checkpoint inhibition for the treatment of renal cell carcinoma
    Stuehler, Viktoria
    Maas, Jan Moritz
    Rausch, Steffen
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 83 - 94
  • [3] Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
    Lindner, Andrea Katharina
    Pichler, Martin
    Thurnher, Martin
    Pichler, Renate
    EUROPEAN UROLOGY, 2022, 81 (01) : 1 - 2
  • [4] Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?
    Reijm, E. A.
    van Thienen, J., V
    Wilgenhof, S.
    Bex, A.
    Haanen, J. B. A. G.
    KIDNEY CANCER, 2019, 3 (04) : 199 - 211
  • [5] Immune checkpoint inhibition in metastatic urothelial carcinoma
    Bedke, Jens
    Todenhoefer, Tilman
    Stenzl, Arnulf
    AKTUELLE UROLOGIE, 2018, 49 (02) : 178 - 186
  • [6] Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma
    Varkaris, Andreas
    Xu, Wenxin
    Davis, Roger B.
    Healy, Brian
    McDermott, David F.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 179 - +
  • [7] Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors
    Tripathi, Abhishek
    Lin, Edwin
    Agarwal, Neeraj
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [8] Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors
    Hanif, Ahmad
    Pandey, Manu
    Khan, Sumera
    Attwood, Kristopher
    George, Saby
    ONCOIMMUNOLOGY, 2019, 8 (08):
  • [9] Lecture 2: Immune checkpoint blockade for metastatic renal cell carcinoma
    Sundaram, Chandru P.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (05) : 403 - 403
  • [10] Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
    Yang, Yuanquan
    Psutka, Sarah P.
    Parikh, Anish B.
    Li, Mingjia
    Collier, Katharine
    Miah, Abdul
    Mori, Sherry, V
    Hinkley, Megan
    Tykodi, Scott S.
    Hall, Evan
    Thompson, John A.
    Yin, Ming
    CANCER MEDICINE, 2022, 11 (16): : 3106 - 3114